CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- PositionReturn on equity is -326.1%, lower than 95% of its Biotechnology peers (median -21.7%)
- FinancialsLow earnings quality
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
457.32MUSDvs all stocks (USD)
Revenue (TTM)
38.69MUSDvs all stocks (USD)
Profit Margin
-281.59%vs Biotechnology peers
Beta
2.10xvs all stocks
52-Week Change
-5.40%vs all stocks
Market Capitalization
457.32MUSDvs all stocks (USD)
Enterprise Value
185.41MUSDvs all stocks (USD)
Forward P/E
-3.18xvs Biotechnology peers
Price to Sales (TTM)
11.82xvs Biotechnology peers
Price to Book (MRQ)
66.22xvs Biotechnology peers
Enterprise to Revenue
4.79xvs Biotechnology peers
Enterprise to EBITDA
-2.18xvs Biotechnology peers
Profit Margin
-281.59%vs Biotechnology peers
Operating Margin
-883.19%vs Biotechnology peers
Return on Assets (TTM)
-26.95%vs Biotechnology peers
Return on Equity (TTM)
-326.07%vs Biotechnology peers
Revenue (TTM)
38.69MUSDvs all stocks (USD)
Revenue per Share (TTM)
0.4190USDUpdated Jul 18, 2026Quarterly Revenue Growth
-39.20%vs Biotechnology peers
Gross Profit (TTM)
-42.27MUSDvs all stocks (USD)
EBITDA (TTM)
-85.19MUSDvs all stocks (USD)
Net Income (TTM)
-108.95MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
-39.22%vs Biotechnology peers
Operating Cash Flow (TTM)
-140.50MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-73.82MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 18, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
40.52MUSDFY2025 · Dec 31, 2025Operating Income
-99.34MUSDvs all stocks (USD)
Pre-tax Income
-160.06MUSDFY2025 · Dec 31, 2025Net Income
-160.06MUSDFY2025 · Dec 31, 2025EBIT
-153.89MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-87.94MUSDFY2025 · Dec 31, 2025Research & Development
89.95MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
49.90MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
8.31MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
6.17MUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
-160.06MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-158.17MUSDFY2025 · Dec 31, 2025Free Cash Flow
-158.51MUSDDerived from operating cash flow minus capital expenditure. This filing charges 5.28M of depreciation against 338K of capital expenditure, and its own free-cash-flow line reads -165.85M.FY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
149.31MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-160.06MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
5.28MUSDFY2025 · Dec 31, 2025Stock-based Compensation
10.00MUSDFY2025 · Dec 31, 2025Other Non-cash Items
5.72MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
1.09MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
-2.89MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-17.31MUSDFY2025 · Dec 31, 2025Capital Expenditures
-338.00KUSDFY2025 · Dec 31, 2025Purchase of Investments
0.00USDFY2025 · Dec 31, 2025Sale of Investments
139.01MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
138.67MUSDFY2025 · Dec 31, 2025Other Financing Charges
-2.87MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
39.98MUSDFY2025 · Dec 31, 2025Shares Outstanding
97.90MSharesUpdated Jul 18, 2026Float Shares
79.28MSharesUpdated Jul 18, 2026Shares Short
22.47MSharesUpdated Jul 18, 2026Short Ratio
8.12daysvs all stocks
Short % of Shares Outstanding
14.67%vs all stocks
% Held by Insiders
0.17%vs all stocks
% Held by Institutions
49.30%vs all stocks
Total Cash (MRQ)
123.65MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
1.26USDUpdated Jul 18, 2026Total Debt (MRQ)
17.30MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
3.92xvs Biotechnology peers
Current Ratio (MRQ)
3.22xvs Biotechnology peers
Book Value per Share (MRQ)
0.0450USDUpdated Jul 18, 2026Total Assets
186.53MUSDvs all stocks (USD)
Total Current Assets
163.90MUSDFY2025 · Dec 31, 2025Total Liabilities
159.25MUSDFY2025 · Dec 31, 2025Total Non-current Assets
22.64MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
113.00MUSDFY2025 · Dec 31, 2025Total Current Liabilities
46.25MUSDFY2025 · Dec 31, 2025Cash Equivalents
146.65MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
146.65MUSDFY2025 · Dec 31, 2025Other Short-term Investments
0.00USDFY2025 · Dec 31, 2025Accounts Receivable
15.18MUSDFY2025 · Dec 31, 2025Accounts Payable
2.60MUSDFY2025 · Dec 31, 2025Short-term Debt
6.03MUSDFY2025 · Dec 31, 2025Deferred Revenue
5.00MUSDFY2025 · Dec 31, 2025Long-term Debt
12.07MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
2.81MUSDFY2025 · Dec 31, 2025Common Stock (Book)
10.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-1.63BUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
27.29MUSDvs all stocks (USD)
52-Week Low
1.66USDUpdated Jul 18, 202652-Week High
4.54USDUpdated Jul 18, 202652-Week Change
-5.40%vs all stocks
Beta
2.10xvs all stocks
50-Day MA
2.96USDUpdated Jul 18, 2026200-Day MA
2.69USDUpdated Jul 18, 2026Avg 10-Day Volume
2.40MSharesUpdated Jul 18, 2026Avg 30-Day Volume
2.63MSharesUpdated Jul 18, 2026Diluted EPS (TTM)
-1.14USDUpdated Jul 18, 2026Other Income / Expense
-62.86MUSDFY2025 · Dec 31, 2025Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Return on equity is -326.1%, lower than 95% of its Biotechnology peers (median -21.7%)Significant
Return on equity: -3.26Industry median: -0.22Industry P5: -1.66Peers compared: 261
Debt-to-equity is 3.92×, higher than 95% of its Biotechnology peers (median 0.09×)Significant
Debt-to-equity: 3.92Industry median: 0.09Industry P95: 0.88Peers compared: 261
Price-to-book is 66.22×, higher than 95% of its Biotechnology peers (median 2.97×)Significant
Price-to-book: 66.22Industry median: 2.97Industry P95: 23.50Peers compared: 261
Structural Tensions
Significant cash reserves alongside high leverageNotable
Cash (USD): 123,648,000Total Debt (USD): 17,297,000Debt-to-Equity: 3.92
Financial Health
Low earnings qualitySignificant
Earnings Quality Score: -0.67
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Guizhou Yibai Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Guanhao Biotech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shaanxi Panlong Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Nanjing Medlander Medical Inc.
Tier 1ProductionApproval-Gated PipelineRule
ClearPoint Neuro Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Anhui Fengyuan Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Zhejiang Shouxiangu Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Ocugen Inc.
Tier 1ProductionApproval-Gated PipelineRule
Ever Supreme Bio Technology Co., Ltd
Tier 1ProductionApproval-Gated PipelineRuleFlow
Prothena Corporation plc
Tier 1ProductionApproval-Gated PipelineRuleRisk